H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection
NCT ID: NCT00926809
Last Updated: 2009-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
232 participants
INTERVENTIONAL
2008-09-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia
NCT00990405
Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD
NCT02407119
Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer
NCT01002443
Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp
NCT03065868
Effect of H. Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients
NCT02691637
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eradication
Helicobacter pylori eradication
Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin
Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
No eradication
No eradication for Helicobacter pylori
Lansoprazole (proton pump inhibitor), placebo
Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin
Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
Lansoprazole (proton pump inhibitor), placebo
Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Early gastric cancer (\< 3 cm in size, mucosa confined, differentiated type) or gastric adenoma (\< 3 cm in size)
* Helicobacter pylori positive
Exclusion Criteria
* History of Helicobacter pylori eradication
* History of gastric surgery or other cancers
* Major comorbidities
* Medication of ASA, NSAIDS, steroids, anti-coagulants
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korean College of Helicobacter and Upper Gastrointestinal Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Korean College of Helicobacter and Upper Gastrointestinal Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyun Chae Jung
Role: PRINCIPAL_INVESTIGATOR
Korean College of Helicobacter and Upper Gastrointestinal Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center Korea
Goyang, , South Korea
Asan Medical Center
Seoul, , South Korea
Korea University Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Soonchunhyang University Hospital
Seoul, , South Korea
Yonsei University Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Il Ju Choi
Role: primary
Hoon Jae Chun
Role: primary
Sang Gyun Kim
Role: primary
Joo Young Cho
Role: primary
Yong Chan Lee
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009KHR001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.